Research programme: haemophilia therapeutics - Shire/Flamel

Drug Profile

Research programme: haemophilia therapeutics - Shire/Flamel

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Baxter International; Flamel Technologies
  • Developer Avadel Pharmaceuticals; Shire
  • Class Blood coagulation factors
  • Mechanism of Action Blood coagulation factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Haemophilia

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 14 Jul 2009 Early research in Haemophilia in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top